Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$136.00 USD
-1.35 (-0.98%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $136.06 +0.06 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KRYS 136.00 -1.35(-0.98%)
Will KRYS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KRYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRYS
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates
KRYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Other News for KRYS
What 8 Analyst Ratings Have To Say About Krystal Biotech
Chardan Capital Maintains Buy Rating for Krystal Biotech (KRYS) | KRYS Stock News
Citigroup Maintains Neutral Rating on KRYS, Lowers Price Target | KRYS Stock News
Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results